GlassScriptPhysician profile
Rajan A Kadakia
NPI 1548295264
$5,025.39
in general payments reported to CMS, 2019-2025
27 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,573 · 2020: $152 · 2021: $692 · 2022: $646 · 2023: $1,145 · 2024: $315 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,962.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $938.00 | 2019-2025 | Mylux Patient Kit With Mobile Device |
| Medtronic, INC. | $662.28 | 2021-2025 | Turbohawk, Protege Rx, In.Pact Admiral |
| Impulse Dynamics (USA) INC. | $498.32 | 2023-2024 | Optimizer, Optimizer |
| Abbott Laboratories | $420.94 | 2019-2020 | |
| Medtronic Vascular, INC. | $367.35 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $356.06 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $271.97 | 2019-2025 | |
| Amarin Pharma, INC. | $147.17 | 2019-2022 | |
| Biotronik INC. | $136.96 | 2021 | |
| Abiomed | $136.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.67 | 2021-2023 | Jardiance |
| Edwards Lifesciences Corporation | $119.65 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $109.89 | 2019-2024 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $106.95 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $87.74 | 2022-2023 | Verquvo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $73.09 | 2023-2025 | Ozempic |
| Lexicon Pharmaceuticals, INC. | $70.30 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $67.07 | 2021 | |
| Sanofi-Aventis U.S. LLC | $61.15 | 2019-2024 | |
| Amgen INC. | $60.51 | 2023-2024 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $54.04 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $49.40 | 2023-2024 | |
| Pfizer INC. | $44.02 | 2022-2023 | |
| Neural Analytics, INC. | $17.82 | 2019 | |
| Gilead Sciences, INC. | $15.51 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.64 | 2021 | |
| Zoll Circulation INC | $9.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajan Kadakia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.